$0.28
-0.01 (-3.82%)
Open$0.27
Previous Close$0.29
Day High$0.28
Day Low$0.23
52W High$2.75
52W Low$0.23
Volume—
Avg Volume9.81M
Market Cap2.51M
P/E Ratio—
EPS$-4.21
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+13,604.9% upside
Current
$0.28
$0.28
Target
$37.99
$37.99
$25.94
$37.99 avg
$62.46
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 17.93M | 14.21M | 257.5K |
| Net Income | -36,017,500 | -25,683,979 | -16,876 |
| Profit Margin | -200.8% | -190.8% | -6.6% |
| EBITDA | -35,929,696 | -27,044,775 | -21,131 |
| Free Cash Flow | — | — | -13,268 |
| Rev Growth | +26.2% | +26.2% | +2.0% |
| Debt/Equity | 0.08 | 0.08 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |